ViiV’s four-monthly HIV drug maintains viral suppression at 12 months

ViiV Healthcare has reported several successful HIV trials at CROI 2026, including its investigational candidates lotivibart, ...
Yahoo

HIV patients show lower steatotic liver disease with ViiV’s Dovato vs Biktarvy

Add Yahoo as a preferred source to see more of our stories on Google. ViiV Healthcare presented the data on the Dovato study at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI ...
Seeking Alpha

ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026

First-in-human data for long-acting formulations of VH184, the first third-generation integrase inhibitor, and early data for capsid inhibitor VH499 to be presented, highlighting progress in ViiV’s ...
The Motley Fool

Intel Lost Money Again in 2025. Here's Why -- and What It Means for the Stock

Intel stock has rebounded sharply over the past year. However, the company's fundamental business metrics haven't yet recovered fully. Investors are banking on continued momentum from AI. The stock ...
HotHardware

Intel Reportedly Wins Slice Of NVIDIA's 2028 GPU Chip Packaging In Strategy Shift

Intel may take on a limited role in manufacturing and packaging NVIDIA's next-next-generation GPUs, according to a report from DigiTimes Asia. Citing supply chain sources, DigiTimes reports that ...
The Motley Fool

The Intel Business Growing 50% That Nobody's Talking About

Intel has rapidly grown its custom ASIC business, exiting 2025 at a $1 billion run rate. Soaring demand for networking AI chips has driven much of the demand. This is a $100 billion market opportunity ...
IGN

Intel Could Take the Handheld Crown From AMD With Panther Lake

Intel technically revealed Panther Lake back in October 2025, leading with the Xe 3 graphics architecture, which Intel claimed was a massively improved integrated graphics chip. Well, shortly after ...
Ars Technica

Demand for Intel’s processors is apparently there, but the supply is not

Intel reported its earnings for the fourth quarter of 2025 yesterday, and the news both for the quarter and for the year was mixed: year-over-year revenue was down nearly imperceptibly, from $53.1 ...
CNBC

Intel stock plunges 13% on soft guidance, concerns about chip production

Intel reported fourth-quarter earnings that beat Wall Street expectations but offered soft guidance for the current quarter. The company provided guidance for first-quarter revenue and earnings per ...
Investopedia

Intel Rallies Ahead of Earnings. Here's What Analysts Are Saying That's Boosting the Stock.

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...
FiercePharma

Pfizer unleashes its stake in GSK's ViiV Healthcare for $1.9B

Five weeks after telling investors to expect a revenue decline in 2026, Pfizer has found a quick funding fix, selling off its stake in GSK’s ViiV Healthcare. The New York powerhouse has agreed to ...